Premium
Chronic necrotizing pulmonary aspergillosis in a patient treated with a tumor necrosis factor‐α inhibitor
Author(s) -
LEE Eun Jung,
SONG Ran,
PARK JiNa,
LEE YeonAh,
SON Jun Seong,
HONG SeungJae,
YANG HyungIn,
LEE SangHoon
Publication year - 2010
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/j.1756-185x.2010.01528.x
Subject(s) - medicine , pulmonary aspergillosis , tumor necrosis factor alpha , aspergillosis , necrosis , tumor necrosis factor α , pathology , immunology
Tumor necrosis factor (TNF)‐α is a pro‐inflammatory cytokine that plays an important role in the pathogenesis of a variety of autoimmune diseases. TNF‐α inhibitors have been shown to offer clinical benefits in the treatment of autoimmune and inflammatory disorders, including rheumatoid arthritis, ankylosing spondylitis (AS), and Crohn’s disease. Occasionally, these agents have been associated with infectious complications because of their immunosuppressive activity. Globally, several cases of infections associated with TNF‐α inhibitors have been reported. However, Aspergillus infection associated with etanercept is very rare. We report a case of chronic necrotizing pulmonary aspergillosis in a 51‐year‐old man with AS that developed after treatment with etanercept.